T. J. Fraites

Improved method of recombinant AAV2 delivery for systemic targeted gene therapy.

Jon Dobson, Sihong Song, Terence R Flotte, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

A new method for recombinant adeno-associated virus vector delivery to murine diaphragm.

B. Byrne, C. Mah, T. J. Fraites, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

B. Byrne, C. Mah, T. J. Fraites, 2005, Gene Therapy.

Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

T. Conlon, B. Byrne, D. Fuller, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.

B. Byrne, M. Atkinson, C. Mah, 2005, Human gene therapy.

Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease

B. Byrne, T. J. Fraites, I. Zolotukhin, 2004, Development.

Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.

B. Byrne, N. Raben, P. Kessler, 2001, Human gene therapy.

Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.

W. Hauswirth, B. Byrne, N. Muzyczka, 2002, Methods.

Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.

B. Byrne, S. Powers, N. Raben, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

B. Byrne, C. Mah, T. J. Fraites, 2005, Gene Therapy.